Last updated on July 2019

A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)


Brief description of study

The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that of a tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC).

Clinical Study Identifier: NCT03729245

Find a site near you

Start Over

Investigator Site - Goodyear

Goodyear, AZ United States
  Connect »

Investigator Site - Whittier

Whittier, CA United States
  Connect »

Investigator Site - Kettering

Kettering, OH United States
  Connect »

Investigator Site - Portland

Portland, OR United States
  Connect »

Investigator Site - Houston

Houston, TX United States
  Connect »

Investigator Site - Fairfax

Fairfax, VA United States
  Connect »

Investigator Site - Leesburg

Leesburg, VA United States
  Connect »

Investigator Site - Saint Petersburg

Saint Petersburg, Russian Federation
  Connect »

Investigator Site - Little Rock

Little Rock, AR United States
  Connect »

Investigator Site - East Setauket

East Setauket, NY United States
  Connect »

Investigator Site - Allentown

Allentown, PA United States
  Connect »

Investigator Site - Chattanooga

Chattanooga, TN United States
  Connect »

Investigator Site - Anchorage

Anchorage, AK United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.